Vaccines for the prevention of meningococcal disease in children

Vaccination News Home Page

http://www2.us.elsevierhealth.com/scripts/om.dll/serve?action=searchDB&searchDBfor=art&artType=abs&id=aspid0130182&nav=abs

W.B. Saunders Periodicals Home Search User
Pref		 Help
Sem Ped Infect Dis Home Table of
Contents 		All Issues Order About this
Journal 		<<
Issue 		>>
Issue


 

 

   

July 2002 • Volume 13 • Number 3

 


 

Vaccines for the prevention of meningococcal disease in children

M. Soriano-Gabarró, MD, MSc1 [MEDLINE LOOKUP]
James M. Stuart, MB2 [MEDLINE LOOKUP]
Nancy E. Rosenstein, MD1 [MEDLINE LOOKUP]

• Previous article in Issue
• Next article in Issue
• View full-text version
• View print version (PDF)
• Drug links from Mosby's DrugConsult
• Genetic information from OMIM
• Citation of this Article
   • View on PubMed
   • Download in citation manager format
   • Download in Medlars format
• Related articles in PubMed
 


 

   Abstract  TOP 

Neisseria meningitidis is one of the most feared infections in pediatrics as the result of its rapid progression, high fatality rate, and frequent occurrence of sequelae. The 5 major meningococcal serogroups associated with disease are A, B, C, Y, and W-135. Currently available polysaccharide vaccines are effective in preventing disease caused by serogroups A, C, Y, and W-135 in older children and adults but do not elicit good long-term protection in young children. Vaccines that protect against serogroup B disease are still in development. As with the Haemophilus influenzae type b and pneumococcal polysaccharide vaccines, conjugation of the polysaccharide vaccine to a protein carrier dramatically changes vaccine characteristics, with resulting efficacy in infants. New meningococcal conjugate vaccines against serogroups A, C, Y, and W-135 are being developed. A serogroup C conjugate vaccine has been introduced successfully into the routine childhood schedule in the United Kingdom. New meningococcal conjugate vaccines are likely to have a dramatic effect on the burden of meningococcal disease within the next decade.
Copyright 2002, Elsevier Science (USA). All rights reserved.

 

   Publishing and Reprint Information  TOP 
  • From the 1Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, GA, and 2Communicable Disease Surveillance Centre (South West), Public Health Laboratory, Gloucestershire Royal Hospital, Gloucestershire, UK.
     
  • Address correspondence to Montse Soriano-Gabarró, MD, MSc, Meningitis and Special Pathogens Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, MS C-09, Atlanta, GA 30333, e-mail: zzd7@cdc.gov .
     
  • Copyright 2002, Elsevier Science (USA). All rights reserved.
     
  • 1045-1870/02/1303-0008$35.00/0
     
  • doi:10.1053/spid.2002.125861


 

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.